来源:http://www.fsbygjy.com 日期:2021/9/2点击量:1279
来源:风湿病与关节炎,2021,10(7):8-10,37.
通督升阳三联疗法联合塞来昔布治疗急性活动期强直性脊柱炎27例临床观察(临床研究)
李国瑛1,唐 慧1,李 翼2
【摘 要】目的:观察中医通督三联疗法联合塞来昔布治疗强直性脊柱炎急性活动期的临床疗效。方法:将53例急性活动期强直性脊柱炎患者随机分为治疗组27例和对照组26例。对照组口服塞来昔布胶囊治疗,治疗组在对照组基础上采用通督升阳三联疗法(即口服中药通督升阳汤、针灸通督疗法、正清风痛宁注射液腰宜穴深部注射)治疗。2组均以8周为1个疗程。观察2组临床疗效,以及治疗前后临床症状(枕墙距、指地距、胸廓扩张度)和实验室指标(红细胞沉降率、C反应蛋白)。结果:治疗组好转12例,显效8例,有效5例,无效2例,总有效率为92.59%;对照组好转6例,显效6例,有效8例,无效6例,总有效率为76.92%。2组比较,差异有统计学意义(P < 0.05)。治疗后,2组枕墙距、指地距、胸廓扩张度、红细胞沉降率、C反应蛋白较治疗前均有改善(P < 0.05);且治疗组优于对照组(P < 0.05)。结论:通督升阳三联疗法联合塞来昔布治疗强直性脊柱炎急性活动期患者能提高疗效,明显改善临床症状和实验室指标。
【关键词】 强直性脊柱炎;急性活动期;通督升阳;三联疗法;临床疗效
Clinical Observation of 27 Cases of Acute Active Ankylosing Spondylitis Treated with Tongdu Shengyang Triple Therapy Combined with Celecoxib
LI Guo-ying,TANG Hui,LI Yi
【ABSTRACT】Objective:To observe the clinical efficacy of Tongdu Shengyang Triple Therapy combined with celecoxib in the treatment of active ankylosing spondylitis.Methods:Fifty-three patients with acute active ankylosing spondylitis were randomly divided into a treatment group(27 cases)and a control group(26 cases).The control group was treated with celecoxib capsule,and the treatment group was treated with Tongdu Shengyang Triple Therapy(Tongdu Shengyang Tang—通督升阳汤,acupuncture and moxibustion for the Governor Vessel,deep acupoint injection of Zhengqing Fengtongning—正清风痛宁),based on the treatment for the control group.Both groups were treated for eight weeks as a course of treatment.The clinical efficacy,clinical symptoms(occipital wall distance,finger ground distance,thoracic expansion)before and after treatment and laboratory indexes(erythrocyte sedimentation rate,C-reactive protein)were observed.Results:In the treatment group,12 cases were improved,8 cases were markedly effective,5 cases were effective,2 cases were ineffective,and the total effective rate was 92.59%;In the control group,6 cases were improved,6 cases were markedly effective,8 cases were effective,6 cases were ineffective,and the total effective rate was 76.92%.The difference between the two groups was statistically significant(P < 0.05).After treatment,occipital wall distance,finger ground distance,thoracic dilatation,erythrocyte sedimentation rate and C-reactive protein of the two groups were improved compared with those before treatment(P < 0.05),and the treatment group was better than the control group(P < 0.05).Conclusion:Tongdu Shengyang Triple Therapy combined with celecoxib in the treatment of active ankylosing spondylitis can improve the curative effect,clinical symptoms and laboratory indicators.
【Keywords】 ankylosing spondylitis;acute active phase;Tongdu Shengyang;Triple Therapy;clinical efficacy
![]() |